Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma
Clinical trial NCT05498220 · TERMINATED
Trial details
- NCT number
- NCT05498220
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-02-17
- Primary completion
- 2025-03-07
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.